CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal

Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC: CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year increase of 700%.

Q2 Financial Highlights

  • Gross profit hit $1.31 million during the second quarter of fiscal 2021, representing a 676% growth compared to the same quarter of 2020.
  • Net loss from operations of $3.27 million improved substantially compared to a net loss from operations of $13.47 million a year ago.

Q2 2021 Operational Highlights

  • Sera Labs, which Cure Pharmaceutical bought last year for an …

Full story available on Benzinga.com

More CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal